Switching Australian patients with moderate to severe inflammatory bowel disease from originator infliximab to biosimilar Inflectra: Interim results from a multicenter parallel cohort study

被引：0
|
作者：
Haifer, C. [1 ,2 ]
Srinivasan, A. [3 ,4 ]
Menon, S. [5 ]
An, Y. [9 ]
Picardo, S. [8 ]
Van Langenberg, D.
Begun, J. [8 ,9 ]
Ghaly, S. [1 ]
Thin, L. [6 ,7 ]
机构：
[1] St Vincents Hosp, Melbourne, Vic, Australia
[2] Univ Sydney, Sydney, NSW, Australia
[3] Eastern Hlth, Box Hill, Vic, Australia
[4] Monash Univ, Melbourne, Vic, Australia
[5] Royal Perth Hosp, Perth, WA, Australia
[6] Fiona Stanley Hosp, Murdoch, WA, Australia
[7] Univ Western Australia, Perth, WA, Australia
[8] Mater Hosp, Brisbane, Qld, Australia
[9] Univ Queensland, Brisbane, Qld, Australia
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2019年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
217
引用
收藏
页码：155 / 156
页数：2
相关论文
共 50 条
  • [21] Biosimilar infliximab in inflammatory bowel diseases: first interim Results from a prospective nationwide observational cohort
    Gecse, K.
    Farkas, K.
    Lovasz, B.
    Banai, J.
    Bene, L.
    Gasztonyi, B.
    Golovics, P. A.
    Kristof, T.
    Lakatos, L.
    Miheller, P.
    Nagy, F.
    Palatka, K.
    Papp, M.
    Patai, A.
    Salamon, A.
    Szamosi, T.
    Szepes, Z.
    Toth, G. T.
    Vincze, A.
    Molnar, T.
    Lakatos, P.
    JOURNAL OF CROHNS & COLITIS, 2015, 9 : S234 - S235
  • [22] Biosimilar Infliximab in Inflammatory Bowel Diseases: First Interim Results From a Prospective Nationwide Observational Cohort
    Gecse, Krisztina
    Farkas, Klaudia
    Lovasz, Barbara D.
    Banai, Janos
    Golovics, Petra A.
    Kristof, Tunde
    Lakatos, Laszlo
    Miheller, Pal
    Palatka, Karoly
    Papp, Maria
    Szamosi, Tamas
    Szepes, Zoltan
    Vincze, Aron
    Molnar, Tamas
    Lakatos, Peter L.
    GASTROENTEROLOGY, 2015, 148 (04) : S865 - S866
  • [23] SWITCHING FROM INFLIXIMAB ORIGINATOR TO THE BIOSIMILAR (CT-P13) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A RETROSPECTIVE STUDY ABOUT EFFECTIVENESS AND SAFETY
    Annulli, G.
    Quatraccioni, C.
    Daretti, L. M.
    Antuono, S.
    Guardati, P.
    Calzolari, M.
    Benedetti, A.
    Di Sario, A.
    DIGESTIVE AND LIVER DISEASE, 2020, 52 : S134 - S135
  • [24] Analysis of the effectiveness and safety of switching from originator to biosimilar adalimumab in patients with Inflammatory Bowel Disease
    Casanova, M. J.
    Chaparro, M.
    Nantes, O.
    Varela, P.
    Vela-Gonzalez, M.
    Montserrat, R.
    Sierra, O. G.
    Riestra, S.
    Barreiro-de Acosta, M.
    Martin-Rodriguez, M. M.
    Gargallo-Puyuelo, C. J.
    Reygosa, C.
    Munoz, R.
    Garcia de la Filia-Molina, I.
    Nunez-Ortiz, A.
    Kolle, L.
    Calafat, M.
    Huguet, J. M.
    Iglesias-Flores, E.
    Martinez-Perez, T. J.
    Bosch, O.
    Duque-Alcorta, J. M.
    Frago-Larramona, S.
    Sanchez-Azofra, M.
    Van Domselaar, M.
    Gonzalez-Cosano, V. M.
    Bujanda, L.
    Rubio, S.
    Mancebo, A.
    Castro, B.
    Garcia-Lopez, S.
    de Francisco, R.
    Nieto, L.
    Laredo, V.
    Gutierrez, A.
    Mesonero, F.
    Leo-Carnerero, E.
    Canete, F.
    Ruiz, L.
    Gisbert, J. P.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I474 - I475
  • [25] Analysis of the effectiveness and safety of switching from originator to biosimilar adalimumab in patients with Inflammatory Bowel Disease
    Casanova, M. J.
    Chaparro, M.
    Nantes, O.
    Varela, P.
    Vela-Gonzalez, M.
    Montserrat, R.
    Sierra, O. G.
    Riestra, S.
    Barreiro-de Acosta, M.
    Martin-Rodriguez, M. M.
    Gargallo-Puyuelo, C. J.
    Reygosa, C.
    Munoz, R.
    Garcia de la Filia-Molina, I.
    Nunez-Ortiz, A.
    Kolle, L.
    Calafat, M.
    Huguet, J. M.
    Iglesias-Flores, E.
    Martinez-Perez, T. J.
    Bosch, O.
    Duque-Alcorta, J. M.
    Frago-Larramona, S.
    Sanchez-Azofra, M.
    Van Domselaar, M.
    Gonzalez-Cosano, V. M.
    Bujanda, L.
    Rubio, S.
    Mancebo, A.
    Castro, B.
    Garcia-Lopez, S.
    de Francisco, R.
    Nieto, L.
    Laredo, V.
    Gutierrez, A.
    Mesonero, F.
    Leo-Carnerero, E.
    Canete, F.
    Ruiz, L.
    Gisbert, J. P.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I474 - I475
  • [26] Efficacy and safety of switching between originator and biosimilar infliximab in patients with inflammatory bowel disease in practical clinic: results to 6 months
    Diaz Hernandez, L.
    Rodriguez Gonzalez, G. E.
    Vela Gonzalez, M.
    Tardillo Marin, C. A.
    Rodriguez Diaz, C. Y.
    Arranz Hernandez, L.
    Montero Delgado, J. A.
    San Juan Acosta, M.
    Perez Hernandez, F.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S327 - S327
  • [27] Reverse switching from the biosimilar SB2 to the originator infliximab in previously switched patients with inflammatory bowel diseases: results of a prospective long-term cohort study
    Fischer, Sarah
    Donhauser, Moritz
    Cohnen, Sarah
    Fietkau, Konstantin
    Vetter, Marcel
    Gruebel-Liehr, Maria
    Dietrich, Peter
    Rath, Timo
    Wilfer, Angelika
    Sologub, Ludmilla
    Krebs, Sabine
    Doerje, Frank
    Nagore, Daniel
    Meyer, Sebastian
    Neurath, Markus F.
    Atreya, Raja
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2024, 17
  • [28] Reverse switching from the biosimilar SB2 to the originator infliximab in previously switched patients with inflammatory bowel diseases: results of a prospective long-term cohort study
    Fischer, Sarah
    Donhauser, Moritz
    Cohnen, Sarah
    Fietkau, Konstantin
    Vetter, Marcel
    Gruebel-Liehr, Maria
    Dietrich, Peter
    Rath, Timo
    Wilfer, Angelika
    Sologub, Ludmilla
    Krebs, Sabine
    Doerje, Frank
    Nagore, Daniel
    Meyer, Sebastian
    Neurath, Markus F.
    Atreya, Raja
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2024, 17
  • [29] The Safety of Switching From Originator Infliximab or Biosimilar CT-P13 to SB2 Among a Nationwide Cohort of Inflammatory Bowel Disease Patients
    Pernes, Tyler
    Patel, Manthankumar
    Khan, Nabeel
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S405 - S405
  • [30] Multiple Switches From the Originator Infliximab to Biosimilars Is Effective and Safe in Inflammatory Bowel Disease: A Prospective Multicenter Cohort Study
    Hanzel, Jurij
    Jansen, Jeroen M.
    ter Steege, Rinze W. F.
    Gecse, Krisztina B.
    D'Haens, Geert R.
    INFLAMMATORY BOWEL DISEASES, 2022, 28 (04) : 495 - 501
12345